HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Clinical trial NCT03326921 · RECRUITING

Trial details

NCT number: NCT03326921
Sponsor: Fred Hutchinson Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Juvenile Myelomonocytic Leukemia Recurrent Acute Biphenotypic Leukemia Recurrent Acute Undifferentiated Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Lymphoblastic Leukemia Refractory Adult Acute Lymphoblastic Leukemia Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recurrent Myelodysplastic Syndrome Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory Myelodysplastic Syndrome

Start date: 2018-02-23
Primary completion: 2027-10-16
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.